Aramchol's Failed Past Isn't Its Future; Galmed Gets An Upgrade By: Benzinga via Benzinga March 15, 2018 at 13:12 PM EDT Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) lost a bull in February on Aramchol’s failed ARRIVE study for HIV-related fatty liver ... Read More >> Related Stocks: Galmed Pharmaceutica
